Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm [clinicaltrials:NCT00276315]

Bio2RDF uri

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm [clinicaltrials:NCT00276315]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00276315

Bio2RDF identifier

NCT00276315

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00276315

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00276315

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:245b0106e3be1922b847a6799a540c10

brief summary [clinicaltrials_vocabulary:brief-summary]

To compare the effectiv ...... nt of hemifacial spasm.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels) At the end of week 4 [clinicaltrials_resource:35eb20532cd1f58f5db9989f5cedcd8f]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels) At the end of week 4 [clinicaltrials_resource:097f658c12950c9bd53b97f85dfef647]

Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels) At the end of week 4 [clinicaltrials_resource:0e31a2ac2122b74116093b662f5abf87]

Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels) At the end of week 4 [clinicaltrials_resource:4678296619db26a7e4a6ce30a98fec3b]

completion date [clinicaltrials_vocabulary:completion-date]

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00276315 [clinicaltrials_resource:9596a3f3dff38492f48157c17f00e9e3]

enrollment [clinicaltrials_vocabulary:enrollment]

348

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Botulinum type A toxin (Dysport®) - one single injection [clinicaltrials_resource:dbbffe872011a497ba5217a66dece2dc]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Botulinum Toxins, Type A [clinicaltrials_resource:edca97403b813ba86b3d465f46f84466]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2007-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

location [clinicaltrials_vocabulary:location]

Neurology Department, Peking Union Medical College Hospital [clinicaltrials_resource:9ac9520473bda19618373d6426062af8]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00276315

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Phase III, Multicentre, Rand ...... Treatment of Hemifacial Spasm

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

A-38-52120-074

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Jing-dong Ma, MD [clinicaltrials_resource:0946434645a7c3d0c8fdecd7ef5f06c9]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

China: Food and Drug Administration [clinicaltrials_resource:c7a9e75495ed866768e97b10c53c1472]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

source [clinicaltrials_vocabulary:source]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

start date [clinicaltrials_vocabulary:start-date]

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00276315 study design [clinicaltrials_resource:a3f488681efb063cdd0de734e647a607]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00276315

verification date [clinicaltrials_vocabulary:verification-date]

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00276315

http://www.w3.org/2001/XMLSchema#string

title

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Assessment of Effectiveness an ...... m [clinicaltrials:NCT00276315]

@en